Korean Biotechs Build Early Stage Novel Research
This article was originally published in PharmAsia News
Novel R&D at several South Korean bioventures is marching on amid the government’s push to nurture the biotech sector. Cellid, ViroMed and Oscotec have all recently unveiled notable progress in their early stage research in immune-oncology, motor neuron disease, and targeted cancer therapy respectively.
Register for our free email digests: